Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 225

1.

The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: results from a phase I clinical trial.

Huijts CM, Lougheed SM, Bodalal Z, van Herpen CM, Hamberg P, Tascilar M, Haanen JB, Verheul HM, de Gruijl TD, van der Vliet HJ; Dutch WIN-O Consortium.

Cancer Immunol Immunother. 2019 Jan 17. doi: 10.1007/s00262-018-2288-8. [Epub ahead of print]

PMID:
30652208
2.

Phase I Dose-Escalation Study of Once Weekly or Once Every Two Weeks Administration of High-Dose Sunitinib in Patients With Refractory Solid Tumors.

Rovithi M, Gerritse SL, Honeywell RJ, Ten Tije AJ, Ruijter R, Peters GJ, Voortman J, Labots M, Verheul HMW.

J Clin Oncol. 2018 Dec 26:JCO1800725. doi: 10.1200/JCO.18.00725. [Epub ahead of print]

PMID:
30586316
3.

Bone-Targeting Radiopharmaceuticals as Monotherapy or Combined With Chemotherapy in Patients With Castration-Resistant Prostate Cancer Metastatic to Bone.

Bouman-Wammes EW, de Klerk JMH, Bloemendal HJ, Van Dodewaard-de Jong JM, Lange R, Ter Heine R, Verheul HMW, Van den Eertwegh AJM.

Clin Genitourin Cancer. 2018 Nov 17. pii: S1558-7673(18)30099-5. doi: 10.1016/j.clgc.2018.11.014. [Epub ahead of print] Review.

PMID:
30555024
4.

Impact of Patient- and Clinician-Reported Cumulative Toxicity on Quality of Life in Patients With Metastatic Castration-Naïve Prostate Cancer.

Schuurhuizen CSEW, Marino P, Braamse AMJ, Buffart LM, Joly F, Fizazi K, Habibian M, Boher JM, Soulie M, Oudard S, Konings IRHM, Verheul HMW, Dekker J, Gravis G.

J Natl Compr Canc Netw. 2018 Dec;16(12):1481-1488. doi: 10.6004/jnccn.2018.7069.

PMID:
30545995
5.

Are patient-reported outcomes of physical function a valid substitute for objective measurements?

Douma JAJ, Verheul HMW, Buffart LM.

Curr Oncol. 2018 Oct;25(5):e475-e479. doi: 10.3747/co.25.4080. Epub 2018 Oct 31.

6.

How Does a Supervised Exercise Program Improve Quality of Life in Patients with Cancer? A Concept Mapping Study Examining Patients' Perspectives.

Sweegers MG, Buffart LM, van Veldhuizen WM, Geleijn E, Verheul HMW, Brug J, Chinapaw MJM, Altenburg TM.

Oncologist. 2018 Nov 13. pii: theoncologist.2017-0613. doi: 10.1634/theoncologist.2017-0613. [Epub ahead of print]

PMID:
30425179
7.

Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma.

Huijts CM, Werter IM, Lougheed SM, Goedegebuure RS, van Herpen CM, Hamberg P, Tascilar M, Haanen JB, Verheul HM, de Gruijl TD, van der Vliet HJ; Dutch WIN-O Consortium.

Cancer Immunol Immunother. 2018 Nov 9. doi: 10.1007/s00262-018-2248-3. [Epub ahead of print]

PMID:
30413837
8.

Feasibility, validity and reliability of objective smartphone measurements of physical activity and fitness in patients with cancer.

Douma JAJ, Verheul HMW, Buffart LM.

BMC Cancer. 2018 Oct 29;18(1):1052. doi: 10.1186/s12885-018-4983-4.

9.

Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours.

Plummer R, Verheul HM, De Vos FYFL, Leunen K, Molife LR, Rolfo C, Grundtvig-Sørensen P, De Grève J, Rottey S, Jerusalem G, Italiano A, Spicer J, Dirix L, Goessl C, Birkett J, Spencer S, Learoyd M, Bailey C, Dean E.

Adv Ther. 2018 Nov;35(11):1945-1964. doi: 10.1007/s12325-018-0804-z. Epub 2018 Oct 15.

PMID:
30324586
10.

Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy.

Smeets D, Miller IS, O'Connor DP, Das S, Moran B, Boeckx B, Gaiser T, Betge J, Barat A, Klinger R, van Grieken NCT, Cremolini C, Prenen H, Mazzone M, Depreeuw J, Bacon O, Fender B, Brady J, Hennessy BT, McNamara DA, Kay E, Verheul HM, Maarten N, Gallagher WM, Murphy V, Prehn JHM, Koopman M, Punt CJA, Loupakis F, Ebert MPA, Ylstra B, Lambrechts D, Byrne AT.

Nat Commun. 2018 Oct 5;9(1):4112. doi: 10.1038/s41467-018-06567-6.

11.

The value of tumour debulking for patients with extensive multi-organ metastatic colorectal cancer.

Gootjes EC, Bakkerus L, Ten Tije AJ, Witteveen PO, Buffart TE, Bridgewater JA, Primrose JN, Verhoef C, Verheul HMW.

Eur J Cancer. 2018 Nov;103:160-164. doi: 10.1016/j.ejca.2018.07.012. Epub 2018 Sep 19.

PMID:
30243064
12.

Cancer Cachexia: Identification by Clinical Assessment versus International Consensus Criteria in Patients with Metastatic Colorectal Cancer.

van der Werf A, van Bokhorst QNE, de van der Schueren MAE, Verheul HMW, Langius JAE.

Nutr Cancer. 2018 Sep 20:1-8. doi: 10.1080/01635581.2018.1504092. [Epub ahead of print]

PMID:
30235002
13.

The predictive value of cumulative toxicity for quality of life in patients with metastatic colorectal cancer during first-line palliative chemotherapy.

Schuurhuizen CS, Verheul HM, Braamse AM, Buffart LM, Bloemendal HJ, Dekker J, Konings IR.

Cancer Manag Res. 2018 Aug 29;10:3015-3021. doi: 10.2147/CMAR.S166468. eCollection 2018.

14.

Rscreenorm: normalization of CRISPR and siRNA screen data for more reproducible hit selection.

Bachas C, Hodzic J, van der Mijn JC, Stoepker C, Verheul HMW, Wolthuis RMF, Felley-Bosco E, van Wieringen WN, van Beusechem VW, Brakenhoff RH, de Menezes RX.

BMC Bioinformatics. 2018 Aug 20;19(1):301. doi: 10.1186/s12859-018-2306-z.

15.

A Phase I Trial of a Guadecitabine (SGI-110) and Irinotecan in Metastatic Colorectal Cancer Patients Previously Exposed to Irinotecan.

Lee V, Wang J, Zahurak M, Gootjes E, Verheul HM, Parkinson R, Kerner Z, Sharma A, Rosner G, De Jesus-Acosta A, Laheru D, Le DT, Oganesian A, Lilly E, Brown T, Jones P, Baylin S, Ahuja N, Azad N.

Clin Cancer Res. 2018 Dec 15;24(24):6160-6167. doi: 10.1158/1078-0432.CCR-18-0421. Epub 2018 Aug 10.

PMID:
30097434
16.

Radiomics analysis of pre-treatment [18F]FDG PET/CT for patients with metastatic colorectal cancer undergoing palliative systemic treatment.

van Helden EJ, Vacher YJL, van Wieringen WN, van Velden FHP, Verheul HMW, Hoekstra OS, Boellaard R, Menke-van der Houven van Oordt CW.

Eur J Nucl Med Mol Imaging. 2018 Dec;45(13):2307-2317. doi: 10.1007/s00259-018-4100-6. Epub 2018 Aug 9.

17.

Combination of a six microRNA expression profile with four clinicopathological factors for response prediction of systemic treatment in patients with advanced colorectal cancer.

Neerincx M, Poel D, Sie DLS, van Grieken NCT, Shankaraiah RC, van der Wolf-de Lijster FSW, van Waesberghe JTM, Burggraaf JD, Eijk PP, Verhoef C, Ylstra B, Meijer GA, van de Wiel MA, Buffart TE, Verheul HMW.

PLoS One. 2018 Aug 3;13(8):e0201809. doi: 10.1371/journal.pone.0201809. eCollection 2018.

18.

Serial FLT PET imaging to discriminate between true progression and pseudoprogression in patients with newly diagnosed glioblastoma: a long-term follow-up study.

Brahm CG, den Hollander MW, Enting RH, de Groot JC, Solouki AM, den Dunnen WFA, Heesters MAAM, Wagemakers M, Verheul HMW, de Vries EGE, Pruim J, Walenkamp AME.

Eur J Nucl Med Mol Imaging. 2018 Dec;45(13):2404-2412. doi: 10.1007/s00259-018-4090-4. Epub 2018 Jul 21.

19.

Taste Alterations During Treatment With Protein Kinase Inhibitors: A Pilot Study.

van der Werf A, de van der Schueren MAE, Rovithi M, Labots M, Hashemi SMS, Langius JAE, Verheul HMW.

J Pain Symptom Manage. 2018 Oct;56(4):e1-e4. doi: 10.1016/j.jpainsymman.2018.06.016. Epub 2018 Jul 17. No abstract available.

PMID:
30025935
20.

Selection of Protein Kinase Inhibitors Based on Tumor Tissue Kinase Activity Profiles in Patients with Refractory Solid Malignancies: An Interventional Molecular Profiling Study.

Labots M, Van der Mijn JC, Dekker H, Ruijter R, Pham TV, Van der Vliet HJ, Van der Hoeven JJM, Meijer GA, Verheul HMW.

Oncologist. 2018 Oct;23(10):1135-e118. doi: 10.1634/theoncologist.2018-0263. Epub 2018 Jul 17.

21.

89Zr-labeled CEA-targeted IL-2 variant immunocytokine in patients with solid tumors: CEA-mediated tumor accumulation and role of IL-2 receptor-binding.

van Brummelen EMJ, Huisman MC, de Wit-van der Veen LJ, Nayak TK, Stokkel MPM, Mulder ER, Hoekstra OS, Vugts DJ, Van Dongen GAMS, Verheul HM, Evers S, Tessier JJL, Saro J, Schellens JHM, Menke-van der Houven van Oordt CW.

Oncotarget. 2018 May 15;9(37):24737-24749. doi: 10.18632/oncotarget.25343. eCollection 2018 May 15.

22.

Metachronous Peritoneal Metastases After Adjuvant Chemotherapy are Associated with Poor Outcome After Cytoreduction and HIPEC.

Sluiter NR, Rovers KP, Salhi Y, Vlek SL, Coupé VMH, Verheul HMW, Kazemier G, de Hingh IHJT, Tuynman JB.

Ann Surg Oncol. 2018 Aug;25(8):2347-2356. doi: 10.1245/s10434-018-6539-x. Epub 2018 May 31.

23.

Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab.

van Dijk E, Biesma HD, Cordes M, Smeets D, Neerincx M, Das S, Eijk PP, Murphy V, Barat A, Bacon O, Prehn JHM, Betge J, Gaiser T, Fender B, Meijer GA, McNamara DA, Klinger R, Koopman M, Ebert MPA, Kay EW, Hennessey BT, Verheul HMW, Gallagher WM, O'Connor DP, Punt CJA, Loupakis F, Lambrechts D, Byrne AT, van Grieken NCT, Ylstra B.

J Clin Oncol. 2018 Jul 10;36(20):2052-2060. doi: 10.1200/JCO.2017.77.1782. Epub 2018 May 24.

PMID:
29792754
24.

Noise-Induced Variability of Immuno-PET with Zirconium-89-Labeled Antibodies: an Analysis Based on Count-Reduced Clinical Images.

Jauw YWS, Heijtel DF, Zijlstra JM, Hoekstra OS, de Vet HCW, Vugts DJ, Verheul HM, Boellaard R, Zweegman S, van Dongen GAMS, der Houven van Oordt CWM, Lammertsma AA, Huisman MC.

Mol Imaging Biol. 2018 Dec;20(6):1025-1034. doi: 10.1007/s11307-018-1200-4.

25.

Randomized phase 2 study of gemcitabine and cisplatin with or without vitamin supplementation in patients with advanced esophagogastric cancer.

van Zweeden AA, van Groeningen CJ, Honeywell RJ, Giovannetti E, Ruijter R, Smorenburg CH, Giaccone G, Verheul HMW, Peters GJ, van der Vliet HJ.

Cancer Chemother Pharmacol. 2018 Jul;82(1):39-48. doi: 10.1007/s00280-018-3588-6. Epub 2018 Apr 25.

26.

Platelet function is disturbed by the angiogenesis inhibitors sunitinib and sorafenib, but unaffected by bevacizumab.

Walraven M, Homs MYV, van der Veldt AAM, Dekker H, Koldenhof J, Honeywell R, Barendrecht A, Sebastian SAE, Parr N, Koekman AC, Voest EE, Roest M, Korporaal SJA, Verheul HMW.

Angiogenesis. 2018 May;21(2):325-334. doi: 10.1007/s10456-018-9598-5. Epub 2018 Mar 12.

27.

Evaluation of several methodological challenges in circulating miRNA qPCR studies in patients with head and neck cancer.

Poel D, Buffart TE, Oosterling-Jansen J, Verheul HM, Voortman J.

Exp Mol Med. 2018 Mar 9;50(3):e454. doi: 10.1038/emm.2017.288.

28.

A safety and immunogenicity study of immunization with hVEGF26-104/RFASE in cynomolgus monkeys.

Wentink MQ, Verheul HMW, Griffioen AW, Schafer KA, McPherson S, Early RJ, van der Vliet HJ, de Gruijl TD.

Vaccine. 2018 Apr 5;36(15):2025-2032. doi: 10.1016/j.vaccine.2018.02.066. Epub 2018 Mar 5.

29.

Exploration of the platelet proteome in patients with early-stage cancer.

Sabrkhany S, Kuijpers MJE, Knol JC, Olde Damink SWM, Dingemans AC, Verheul HM, Piersma SR, Pham TV, Griffioen AW, Oude Egbrink MGA, Jimenez CR.

J Proteomics. 2018 Apr 15;177:65-74. doi: 10.1016/j.jprot.2018.02.011. Epub 2018 Feb 10.

30.

Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody.

Jauw YWS, Huisman MC, Nayak TK, Vugts DJ, Christen R, Naegelen VM, Ruettinger D, Heil F, Lammertsma AA, Verheul HMW, Hoekstra OS, van Dongen GAMS, Menke-van der Houven van Oordt CW.

EJNMMI Res. 2018 Jan 22;8(1):6. doi: 10.1186/s13550-018-0358-8.

31.

FDG PET and FES PET Predict PFS on Endocrine Therapy-Letter.

Mammatas LH, van Helden EJ, Verheul HMW, Menke-van der Houven van Oordt CW.

Clin Cancer Res. 2018 Jan 1;24(1):248. doi: 10.1158/1078-0432.CCR-17-2380. No abstract available.

32.

A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vγ9Vδ2-T cells.

de Bruin RCG, Veluchamy JP, Lougheed SM, Schneiders FL, Lopez-Lastra S, Lameris R, Stam AG, Sebestyen Z, Kuball J, Molthoff CFM, Hooijberg E, Roovers RC, Santo JPD, van Bergen En Henegouwen PMP, Verheul HMW, de Gruijl TD, van der Vliet HJ.

Oncoimmunology. 2017 Oct 20;7(1):e1375641. doi: 10.1080/2162402X.2017.1375641. eCollection 2017.

33.

A randomised phase II trial of docetaxel versus docetaxel plus carboplatin in patients with castration-resistant prostate cancer who have progressed after response to prior docetaxel chemotherapy: The RECARDO trial.

Bouman-Wammes EW, van den Berg HP, de Munck L, Beeker A, Smorenburg CH, Vervenne WL, Coenen JLLM, Verheul HMW, Gerritsen WR, Van den Eertwegh AJM.

Eur J Cancer. 2018 Feb;90:1-9. doi: 10.1016/j.ejca.2017.11.021. Epub 2017 Dec 18.

PMID:
29268139
34.

Higher Muscle Strength Is Associated with Prolonged Survival in Older Patients with Advanced Cancer.

Versteeg KS, Blauwhoff-Buskermolen S, Buffart LM, de van der Schueren MAE, Langius JAE, Verheul HMW, Maier AB, Konings IR.

Oncologist. 2018 May;23(5):580-585. doi: 10.1634/theoncologist.2017-0193. Epub 2017 Dec 8.

PMID:
29222198
35.

Patient-Reported Symptom Monitoring During Chemotherapy.

Douma JAJ, Buffart LM, Verheul HMW.

JAMA. 2017 Nov 21;318(19):1935. doi: 10.1001/jama.2017.14899. No abstract available.

PMID:
29164248
36.

Effect of Neoadjuvant Chemoradiotherapy on Health-Related Quality of Life in Esophageal or Junctional Cancer: Results From the Randomized CROSS Trial.

Noordman BJ, Verdam MGE, Lagarde SM, Hulshof MCCM, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, van Laarhoven HWM, Nieuwenhuijzen GAP, Hospers GAP, Bonenkamp JJ, Cuesta MA, Blaisse RJB, Busch OR, Ten Kate FJW, Creemers GM, Punt CJA, Plukker JTM, Verheul HMW, Spillenaar Bilgen EJ, van Dekken H, van der Sangen MJC, Rozema T, Biermann K, Beukema JC, Piet AHM, van Rij CM, Reinders JG, Tilanus HW, Steyerberg EW, van der Gaast A, Sprangers MAG, van Lanschot JJB.

J Clin Oncol. 2018 Jan 20;36(3):268-275. doi: 10.1200/JCO.2017.73.7718. Epub 2017 Nov 21.

PMID:
29161204
37.

The effects of systemic treatment with aminobisphosphonates and statins on circulating Vγ9Vδ2-T cells in patients with advanced cancer.

Schneiders FL, Huijts CM, Reijm M, Bontkes HJ, Verheul HMW, de Gruijl TD, van der Vliet HJ.

Immunobiology. 2018 Feb;223(2):171-177. doi: 10.1016/j.imbio.2017.10.029. Epub 2017 Oct 16.

PMID:
29055564
38.

Immunological effects of everolimus in patients with metastatic renal cell cancer.

Huijts CM, Santegoets SJ, de Jong TD, Verheul HM, de Gruijl TD, van der Vliet HJ.

Int J Immunopathol Pharmacol. 2017 Dec;30(4):341-352. doi: 10.1177/0394632017734459. Epub 2017 Oct 9.

39.

Insight in taste alterations during treatment with protein kinase inhibitors.

van der Werf A, Rovithi M, Langius JAE, de van der Schueren MAE, Verheul HMW.

Eur J Cancer. 2017 Nov;86:125-134. doi: 10.1016/j.ejca.2017.09.006. Epub 2017 Oct 4. Review.

PMID:
28987769
40.

Decoy receptor 1 (DCR1) promoter hypermethylation and response to irinotecan in metastatic colorectal cancer.

Bosch LJW, Trooskens G, Snaebjornsson P, Coupé VMH, Mongera S, Haan JC, Richman SD, Koopman M, Tol J, de Meyer T, Louwagie J, Dehaspe L, van Grieken NCT, Ylstra B, Verheul HMW, van Engeland M, Nagtegaal ID, Herman JG, Quirke P, Seymour MT, Punt CJA, van Criekinge W, Carvalho B, Meijer GA.

Oncotarget. 2017 Jun 27;8(38):63140-63154. doi: 10.18632/oncotarget.18702. eCollection 2017 Sep 8.

41.

Androgen and Estrogen Receptor Imaging in Metastatic Breast Cancer Patients as a Surrogate for Tissue Biopsies.

Venema CM, Mammatas LH, Schröder CP, van Kruchten M, Apollonio G, Glaudemans AWJM, Bongaerts AHH, Hoekstra OS, Verheul HMW, Boven E, van der Vegt B, de Vries EFJ, de Vries EGE, Boellaard R, Menke van der Houven van Oordt CW, Hospers GAP.

J Nucl Med. 2017 Dec;58(12):1906-1912. doi: 10.2967/jnumed.117.193649. Epub 2017 Sep 14.

42.

Ablation with irreversible electroporation in patients with advanced perihilar cholangiocarcinoma (ALPACA): a multicentre phase I/II feasibility study protocol.

Coelen RJS, Vogel JA, Vroomen LGPH, Roos E, Busch ORC, van Delden OM, Delft FV, Heger M, van Hooft JE, Kazemier G, Klümpen HJ, van Lienden KP, Rauws EAJ, Scheffer HJ, Verheul HM, Vries J, Wilmink JW, Zonderhuis BM, Besselink MG, van Gulik TM, Meijerink MR.

BMJ Open. 2017 Sep 1;7(9):e015810. doi: 10.1136/bmjopen-2016-015810.

43.

Reply to the letter to the editor 'Specific QOL scales that reflect toxicity-induced impairment are needed in RCTs'.

Schuurhuizen CSEW, Braamse AMJ, Konings IRHM, Sprangers MAG, Ket JCF, Dekker J, Verheul HMW.

Ann Oncol. 2017 Aug 1;28(8):2033-2034. doi: 10.1093/annonc/mdx234. No abstract available.

PMID:
28838215
44.

Phase I Study of Dalteparin in Combination With Sunitinib in Patients With Metastatic Clear Cell Renal Carcinoma.

Wentink MQ, Verheul HMW, Pal SK, George S, Voortman J, Danchaivijitr P, Adelaiye R, Poslinski D, Groman A, Hutson A, Pili R.

Clin Genitourin Cancer. 2017 Jul 14. pii: S1558-7673(17)30201-X. doi: 10.1016/j.clgc.2017.07.004. [Epub ahead of print]

PMID:
28781191
45.

Treatment outcome of patients with recurrent glioblastoma multiforme: a retrospective multicenter analysis.

van Linde ME, Brahm CG, de Witt Hamer PC, Reijneveld JC, Bruynzeel AME, Vandertop WP, van de Ven PM, Wagemakers M, van der Weide HL, Enting RH, Walenkamp AME, Verheul HMW.

J Neurooncol. 2017 Oct;135(1):183-192. doi: 10.1007/s11060-017-2564-z. Epub 2017 Jul 20.

46.

Optimal use of anti-EGFR monoclonal antibodies for patients with advanced colorectal cancer: a meta-analysis.

van Helden EJ, Menke-van der Houven van Oordt CW, Heymans MW, Ket JCF, van den Oord R, Verheul HMW.

Cancer Metastasis Rev. 2017 Jun;36(2):395-406. doi: 10.1007/s10555-017-9668-y. Review.

47.

Identification of patients with cancer with a high risk to develop delirium.

Neefjes ECW, van der Vorst MJDL, Verdegaal BATT, Beekman ATF, Berkhof J, Verheul HMW.

Cancer Med. 2017 Aug;6(8):1861-1870. doi: 10.1002/cam4.1106. Epub 2017 Jul 7.

48.

Muscle mass as a target to reduce fatigue in patients with advanced cancer.

Neefjes ECW, van den Hurk RM, Blauwhoff-Buskermolen S, van der Vorst MJDL, Becker-Commissaris A, de van der Schueren MAE, Buffart LM, Verheul HMW.

J Cachexia Sarcopenia Muscle. 2017 Aug;8(4):623-629. doi: 10.1002/jcsm.12199. Epub 2017 Jun 21.

49.

The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments.

Veluchamy JP, Kok N, van der Vliet HJ, Verheul HMW, de Gruijl TD, Spanholtz J.

Front Immunol. 2017 May 31;8:631. doi: 10.3389/fimmu.2017.00631. eCollection 2017. Review.

50.

Benefits of Using Stereotactic Body Radiotherapy in Patients With Metachronous Oligometastases of Hormone-Sensitive Prostate Cancer Detected by [18F]fluoromethylcholine PET/CT.

Bouman-Wammes EW, van Dodewaard-De Jong JM, Dahele M, Cysouw MCF, Hoekstra OS, van Moorselaar RJA, Piet MAH, Verberne HJ, Bins AD, Verheul HMW, Slotman BJ, Oprea-Lager DE, Van den Eertwegh AJM.

Clin Genitourin Cancer. 2017 Oct;15(5):e773-e782. doi: 10.1016/j.clgc.2017.03.009. Epub 2017 Mar 29.

PMID:
28462855

Supplemental Content

Loading ...
Support Center